Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950766 · ClinicalTrials.gov registry record · Phase 1
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
A Phase 1 study of Kidney Cancer, sponsored by Patrick Ott, MD, PhD.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT02950766: Active Phase 1 study of Kidney Cancer, sponsored by Patrick Ott, MD, PhD.
NCT02950766 is a Phase 1 study of Kidney Cancer that is active but no longer recruiting, run by Patrick Ott, MD, PhD. The registered enrollment target is 19 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02950766, a Phase 1 study of Kidney Cancer, is active but no longer recruiting, sponsored by Patrick Ott, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer. The following intervention will be involved in this study: * Personalized Neoantigen Vaccine * Poly-ICLC (Hiltonol) * Ipilimumab
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG NeoVax
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-03-03 |
| Est. Completion | 2030-05-30 |
| Phase | Phase 1 |
What the registry record for NCT02950766 still lists
NCT02950766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab is the first listed.
NCT02950766 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02950766 about?
NCT02950766 is a clinical study titled "NeoVax Plus Ipilimumab in Renal Cell Carcinoma". This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer. The following intervention will be involved in this study: * Personalized Neoantigen Vaccine * Poly-ICLC (Hiltonol) * Ipilimumab
What is the current status of trial NCT02950766?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-03-03. Estimated completion is 2030-05-30.
What conditions does trial NCT02950766 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT02950766?
The interventions under investigation include: Ipilimumab (DRUG), NeoVax (DRUG).
Who is sponsoring clinical trial NCT02950766?
This trial is sponsored by Patrick Ott, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950766 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02950766's enrollment target sits among peer trials
19 50th of 60 higher than 11 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study of VET3-TGI in Patients With Solid Tumors
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
ACTIVE NOT RECRUITING · Phase 1
-
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI